Explore
Validate
Learn
Other assayAntibody data
- Antibody Data
- Antigen structure
- References [15]
- Comments [0]
- Validations
- Other assay [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MS817PABX - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- MMP9 Monoclonal Antibody (IIA5)
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Description
- MS817PABX targets MMP-9 in IP, and WB applications and shows reactivity with Human, and Rat samples.
- Antibody clone number
- IIA5
Submitted references Rapid, Automated, and Specific Immunoassay to Directly Measure Matrix Metalloproteinase-9-Tissue Inhibitor of Metalloproteinase-1 Interactions in Human Plasma Using AlphaLISA Technology: A New Alternative to Classical ELISA.
The pattern of CD44 and matrix metalloproteinase 9 expression is a useful predictor of ulcerative colitis-associated dysplasia and neoplasia.
Fluorometric immunocapture assay for the specific measurement of matrix metalloproteinase-9 activity in biological samples: application to brain and plasma from rats with ischemic stroke.
In vivo effects of zoledronic acid on oral mucosal epithelial cells.
Human mammary fibroblasts stimulate invasion of breast cancer cells in a three-dimensional culture and increase stroma development in mouse xenografts.
Cardosins improve neuronal regeneration after cell disruption: a comparative expression study.
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes.
Pathogenic sequence for dissecting aneurysm formation in a hypomorphic polycystic kidney disease 1 mouse model.
Time course of matrix metalloproteases and tissue inhibitors in bleomycin-induced pulmonary fibrosis.
Simvastatin suppresses experimental aortic aneurysm expansion.
Improved surgical mesh integration into the rat abdominal wall with arginine administration.
Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease.
Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease.
Effect of gamma-synuclein overexpression on matrix metalloproteinases in retinoblastoma Y79 cells.
Effect of gamma-synuclein overexpression on matrix metalloproteinases in retinoblastoma Y79 cells.
Pulido-Olmo H, Rodríguez-Sánchez E, Navarro-García JA, Barderas MG, Álvarez-Llamas G, Segura J, Fernández-Alfonso M, Ruilope LM, Ruiz-Hurtado G
Frontiers in immunology 2017;8:853
Frontiers in immunology 2017;8:853
The pattern of CD44 and matrix metalloproteinase 9 expression is a useful predictor of ulcerative colitis-associated dysplasia and neoplasia.
AbdElazeem MA, El-Sayed M
Annals of diagnostic pathology 2015 Dec;19(6):369-74
Annals of diagnostic pathology 2015 Dec;19(6):369-74
Fluorometric immunocapture assay for the specific measurement of matrix metalloproteinase-9 activity in biological samples: application to brain and plasma from rats with ischemic stroke.
Hawkins KE, DeMars KM, Yang C, Rosenberg GA, Candelario-Jalil E
Molecular brain 2013 Mar 23;6:14
Molecular brain 2013 Mar 23;6:14
In vivo effects of zoledronic acid on oral mucosal epithelial cells.
Allam E, Allen M, Chu TM, Ghoneima A, Jack Windsor L
Oral diseases 2011 Apr;17(3):291-7
Oral diseases 2011 Apr;17(3):291-7
Human mammary fibroblasts stimulate invasion of breast cancer cells in a three-dimensional culture and increase stroma development in mouse xenografts.
Olsen CJ, Moreira J, Lukanidin EM, Ambartsumian NS
BMC cancer 2010 Aug 19;10:444
BMC cancer 2010 Aug 19;10:444
Cardosins improve neuronal regeneration after cell disruption: a comparative expression study.
Duarte AS, Duarte EP, Correia A, Pires E, Barros MT
Cell biology and toxicology 2009 Apr;25(2):99-108
Cell biology and toxicology 2009 Apr;25(2):99-108
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes.
Travaglino E, Benatti C, Malcovati L, Della Porta MG, Gallì A, Bonetti E, Rosti V, Cazzola M, Invernizzi R
European journal of haematology 2008 Mar;80(3):216-26
European journal of haematology 2008 Mar;80(3):216-26
Pathogenic sequence for dissecting aneurysm formation in a hypomorphic polycystic kidney disease 1 mouse model.
Hassane S, Claij N, Lantinga-van Leeuwen IS, Van Munsteren JC, Van Lent N, Hanemaaijer R, Breuning MH, Peters DJ, DeRuiter MC
Arteriosclerosis, thrombosis, and vascular biology 2007 Oct;27(10):2177-83
Arteriosclerosis, thrombosis, and vascular biology 2007 Oct;27(10):2177-83
Time course of matrix metalloproteases and tissue inhibitors in bleomycin-induced pulmonary fibrosis.
Oggionni T, Morbini P, Inghilleri S, Palladini G, Tozzi R, Vitulo P, Fenoglio C, Perlini S, Pozzi E
European journal of histochemistry : EJH 2006 Oct-Dec;50(4):317-25
European journal of histochemistry : EJH 2006 Oct-Dec;50(4):317-25
Simvastatin suppresses experimental aortic aneurysm expansion.
Kalyanasundaram A, Elmore JR, Manazer JR, Golden A, Franklin DP, Galt SW, Zakhary EM, Carey DJ
Journal of vascular surgery 2006 Jan;43(1):117-24
Journal of vascular surgery 2006 Jan;43(1):117-24
Improved surgical mesh integration into the rat abdominal wall with arginine administration.
Arbos MA, Ferrando JM, Quiles MT, Vidal J, López-Cano M, Gil J, Manero JM, Peña J, Huguet P, Schwartz-Riera S, Reventós J, Armengol M
Biomaterials 2006 Feb;27(5):758-68
Biomaterials 2006 Feb;27(5):758-68
Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease.
Kirkegaard T, Hansen A, Bruun E, Brynskov J
Gut 2004 May;53(5):701-9
Gut 2004 May;53(5):701-9
Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease.
Kirkegaard T, Hansen A, Bruun E, Brynskov J
Gut 2004 May;53(5):701-9
Gut 2004 May;53(5):701-9
Effect of gamma-synuclein overexpression on matrix metalloproteinases in retinoblastoma Y79 cells.
Surgucheva IG, Sivak JM, Fini ME, Palazzo RE, Surguchov AP
Archives of biochemistry and biophysics 2003 Feb 1;410(1):167-76
Archives of biochemistry and biophysics 2003 Feb 1;410(1):167-76
Effect of gamma-synuclein overexpression on matrix metalloproteinases in retinoblastoma Y79 cells.
Surgucheva IG, Sivak JM, Fini ME, Palazzo RE, Surguchov AP
Archives of biochemistry and biophysics 2003 Feb 1;410(1):167-76
Archives of biochemistry and biophysics 2003 Feb 1;410(1):167-76
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 AlphaLISA (r) matrix metalloproteinase (MMP)-9-tissue inhibitor of metalloproteinase (TIMP)-1 interaction immunoassay for detecting recombinant MMP-9 (rMMP-9) and TIMP-1 proteins. (A) Schematic illustration of the cross-titration MMP-9-TIMP-1 template. MMP-9 and TIMP-1 concentrations from 0 to 1,000 ng/mL were used for the optimization of the technique. (B) Results of the rMMP-9-TIMP-1 interaction immunoassay expressed as binding RLU (relative luminescence units) using different concentrations of MMP-9 and TIMP-1 (0, 30, 100, 300, and 1,000 ng/mL). (C) Curve 0-1,000 ng/mL of MMP-9 with a fixed dose of 300 ng/mL TIMP-1. (D) Curve 0-1,000 ng/mL of TIMP-1 with a fixed dose of 300 ng/mL MMP-9. (C,D) assays were repeated twice. Hook point is reached at 300 ng/mL MMP-9 and 300 ng/mL TIMP-1.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5 Comparison between specific matrix metalloproteinase (MMP)-9-tissue inhibitor of metalloproteinase (TIMP)-1 interactions determined by AlphaLISA (r) immunoassay and MMP-9, TIMP-1, and MMP-9/TIMP-1 ratio levels estimated by classical ELISAs in human plasma samples from hypertensive patients with normoalbuminuria versus albuminuria. (A) AlphaLISA (r) MMP-9-TIMP-1 interaction immunoassay expressed as binding RLU (relative luminescence units) in normoalbuminuric ( n = 16) and albuminuric ( n = 20) patients. (B) Receiver-operating characteristics curve for AlphaLISA (r) MMP-9-TIMP-1 immunoassay (AUC = 0.778, 95% CI 0.63-0.93). This curve was used for comparing the ability of the AlphaLISA (r) MMP-9-TIMP-1 immunoassay to predict albuminuria in hypertensive patients. AUC, area under curve; CI, confidence interval. (C) MMP-9 and (D) TIMP-1 levels quantified by standard ELISAs. (E) MMP-9/TIMP-1 ratio estimation. * P < 0.05, ** P < 0.01, and *** P < 0.001 versus albuminuric patients. (F) Gelatinase MMP-9 activity in human plasma, upper panel, representative gelatin zymography gel, bottom panel, densitometric analysis expressed as % of change versus normoalbuminuria. In panels (A,C,D,E) , results are expressed as median values (horizontal line) and the interquartile ranges (box). In panel (F) , results are expressed in bar graph as mean values +- SEM.
